Influenza mRNA Vaccine Development

The global burden of influenza is substantial in terms of mortality, morbidity, and economic disruption. Seasonal influenza viruses circulate annually worldwide, resulting in 3-5 million cases of severe disease and 300000-650000 deaths. Vaccination is considered the best approach to prevent infection with influenza virus. The currently available flu vaccines rely on inactivated viral particles, M2e‐based vaccine, live attenuated influenza vaccine (LAIV) and virus like particle (VLP). These vaccine approaches have a good safety profile with acceptable tolerability. However, they offer limited protection against emerging virus strains. Development of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is necessary for reducing influenza virus prevalence.

mRNA vaccine platform for influenza

To date, several approaches to utilize RNA as an influenza vaccine have been developed. Initial studies of naked unmodified RNA delivered via the intramuscular route has demonstrated only modest protection against influenza. Subsequent studies have shown that re-formulation of mRNA to improve stability, such as incorporating the RNA into nanoparticles or liposomes, may also improve delivery of the mRNA intracellularly so the viral protein can be produced, processed and an antigen-specific immune response generated more readily. As mRNA vaccines can theoretically encode any antigen, they may also facilitate novel antigen-targeting approaches, such as cross-reactive HA epitopes that elicit antibodies that neutralize multiple influenza subtypes. These epitopes, when delivered by an immunogenic, flexible, and scalable method such as mRNA, could provide an effective universal influenza vaccine.

Solutions for influenza

Unlike most vaccines that take several months for production, mRNA vaccine production is incredibly fast once the genetic sequence of the pathogen is known. With in-depth knowledge of influenza virus theory and advanced mRNA vaccine technology, Alfa chemistry has the ability to develop mRNA vaccines with potent immunogenicity, thus enabling efficient intra-host antigen production and facilitating the antibody response to influenza viruses.

Why choose us

Alfa Chemistry guarantees to provide customers with efficient and high-quality influenza mRNA vaccine development solutions. If you have any questions related to mRNA vaccine development, please feel free to contact us.

Our products and services are for research use only and cannot be used for any clinical purposes.

Online Inquiry

Influenza mRNA Vaccine Development

Send A Message